-
Mashup Score: 74Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective - 1 month(s) ago
This up-to-date comprehensive worldwide pharmacovigilance study defines the spectrum, characteristics, and evolution of irAE reporting summarizing over a decade of use. Multiple risk factors and clinical peculiarities for specific irAE have been identified as signals to guide clinical practice and future research.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 58B-Cell Immune Checkpoints Come of Age in Cardio-oncology - 1 month(s) ago
Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine (A.G., J.M.). Yale University School of Medicine, New Haven, CT (A.G.). Correspondance to: Javid J. Moslehi, MD, Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine, 555 Mission Bay Blvd. S., Room 452V San Francisco, CA 94143-3118. Email: Section of Cardio-Oncology and
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Congrats 2 @SarnoffCardio Fellow Alan Gutierrez on this @CircRes Editorial! Immune Checkpoints (IC) go beyond T cell ones (CTLA-4, PD-1). The #MoslehiLab has several projects focused on these new IC! Ping me if you want to learn more! @UCSFCardiology https://t.co/4O90p9u1un https://t.co/QqN06RZawU
-
-
Mashup Score: 74Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective - 1 month(s) ago
This up-to-date comprehensive worldwide pharmacovigilance study defines the spectrum, characteristics, and evolution of irAE reporting summarizing over a decade of use. Multiple risk factors and clinical peculiarities for specific irAE have been identified as signals to guide clinical practice and future research.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet-
Another masterpiece by @DrJESalem & team. Full spectrum of irAE w/ ICI treatment! New insights w/ myocarditis, myositis, MG (overlap syndrome). Shortest duration from initial exposure (31-33 days) & highest mortality (27.6%) @TheLancet @eClinicalMed https://t.co/sQXaihOXgc
-
-
Mashup Score: 23Academic Spotlight: Juan Qin, PhD | UCSF Cardiology - 1 month(s) ago
Juan Qin, PhDCardio-Oncology: A Serendipitous Combination Juan Qin, PhD, (pronounced “JOO-anh CHE
Source: ucsfhealthcardiology.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
Nice @UCSFCardiology academic highlight on @JuanQinMed in the Section of #CardioOnc & immunology in our group. @UCSFCancer @ICOSociety @AHA_Research @AHAScience @ucsfhealth https://t.co/HmW2JXcJwQ
-
-
Mashup Score: 20Moslehi Lab - 6 month(s) ago
About Us We are a group of basic and translational scientists who are interested in the intersection between cardiology and oncology (“Cardio-Oncology”). Because of the explosion of novel immune-based therapies in oncology and their effects on the cardiovascular system, our group has also become interested in the intersection of cardiology and immunology. More fundamentally, we are interested…
Source: cardiooncologylab.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
For the Moslehi Lab @UCSFCardiology, lots to think about! Can we utilize thymus biomakers to predict IO TOX? Can we test in our mouse models? What effect of thymus on auto-reactive T cells against cardiac antigens? if interest in joining us, let me know! https://t.co/xN3qDdqMvA https://t.co/1FkR5ncMUJ
-
-
Mashup Score: 17General Cardiology Fellowship | UCSF Cardiology - 9 month(s) ago
Our mission is to train a diverse grou p of fellows who will become leaders in cardiovascular medicine. Our fellows pursue careers in basic, translational and clinical research, clinical care, teaching/education, administration, industry and policy. We feel that our fellowship can offer something for everyone regardless of their interests. We offer over 10 different options for advanced training, both in ACGME and non-ACGME Fellowships and are able to craft new pathways for fellows who have a particular
Source: ucsfhealthcardiology.ucsf.eduCategories: Cardiologists, Latest HeadlinesTweet-
To all cardiology fellowship applicants. If you want to do academic cardiology w/ a focus in research (& interested in coming to UCSF), please email me. Nearly 700 applications this year! Hard to pick the best 40 for interviews! Info about our program: https://t.co/ZVukrE1UYB https://t.co/WgL2nWAt2A
-
-
Mashup Score: 9Interpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology - 10 month(s) ago
Key WordsanthracyclinecardioprotectionSGLT2 inhibitorThe authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.∗Editorials published in JACC: CardioOncology reflect the views of the authors…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
Very thoughtful editorial by @mvaduganathan & team! The field of #CardioOnc needs more such experts to assess the field w/ a critical eye. @JACCJournals Interpreting Nonrandomized Evidence for Clinical Decision Making in Ca... https://t.co/PFBg3UQilJ
-
-
Mashup Score: 0Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines - Full Text View - ClinicalTrials.gov - 10 month(s) ago
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines – Full Text View.
Source: classic.clinicaltrials.govCategories: Cardiologists, Latest HeadlinesTweet-
Look forward to the results of EMPACT although then again is LVEF even a right endpoint for such studies? @Boehringer @EliLillyandCo https://t.co/QAX8VoTjCW
-
-
Mashup Score: 2Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis - 11 month(s) ago
Managing concomitant respiratory muscle involvement with mechanical ventilation and treating with abatacept and ruxolitinib may reduce severe immune checkpoint inhibitor myocarditis high fatality rates.
Categories: Cardiologists, Latest HeadlinesTweet-
This study has implications for Rx. Our group has developed algorithms w/ janus kinase inhibitors (e.g., ruxolitinib) & abatacept for treatment of ICI-myocarditis. We often follow troponin for response. Major flaws w/ any study just following Troponin I! https://t.co/SzsCNWMGsP
-
-
Mashup Score: 0The next big questions in cancer research - 1 year(s) ago
Our understanding of tumorigenesis and cancer progression as well as clinical therapies for different cancer types have evolved dramatically in recent years. However, even with this progress, there are big challenges for scientists and oncologists to tackle, ranging from unpacking the molecular and cellular mechanisms involved to therapeutics and biomarker development to quality of life in the…
Source: CellCategories: Cardiologists, Latest HeadlinesTweet-
Honored 2 be highlighted by @CellCellPress! #CardioOnc @UCSF @UCSFCardiology @UCSFCancer Also nice to see 2 @kaelin_lab alumni featured! @DanaFarber The next big questions in cancer research https://t.co/RODRVzTOWI https://t.co/ARwkYhifqX
-
Another masterpiece by @DrJESalem & team. Full spectrum of irAE w/ ICI treatment! New insights w/ myocarditis, myositis, MG (overlap syndrome). Shortest duration from initial exposure (31-33 days) & highest mortality (27.6%) @TheLancet @eClinicalMed https://t.co/sQXaihOXgc